Funding news
Gero logo

Gero Raises $17.0M Series A

Recently funded · $17.0M Series aTechnology, Information and MediaUSView source

Get the full Gero company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Preclinical stage AI drug discovery company Gero has secured $17.0M in Series A funding, bolstering its mission to eliminate age-related diseases. The firm leverages artificial intelligence to build clinically relevant disease phenotypes from real-world human data, a process designed to identify diseases with shared biology.

This sophisticated methodology then employs WES-enabled genetic studies on these identified phenotypes. This allows Gero to discover novel targets applicable to several indications at once, offering a multi-faceted approach to tackling complex age-related conditions.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series a rounds

Companies that recently closed a Series a round.

#CompanyAmount
1
Telepatia AI logo

Telepatia AI

$42.0M
2
Cargofy logo

Cargofy

United States

$11.0M
3
NexDash logo

NexDash

Germany

$2.9M
4
SubBase logo

SubBase

United States

$7.0M
5
Andera logo

Andera

United States

$37.0M